Celgene forges cancer pact with CRT; FDA OKs Pfizer's Xeljanz as treatment for psoriatic arthritis
→ Celgene has signed a five-year deal with Cancer Research UK’s subsidiary Cancer Research Technology to discover, develop, and commercialize oncology drugs. The duo will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.